ARS Pharmaceuticals (SPRY) Revenue & Revenue Breakdown
ARS Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$89.15M
Latest Revenue (Q)
$15.72M
Main Segment (Y)
Product
ARS Pharmaceuticals Revenue by Period
ARS Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $89.15M | 297063.33% |
| 2023-12-31 | $30.00K | -97.72% |
| 2022-12-31 | $1.32M | -76.10% |
| 2021-12-31 | $5.51M | -69.13% |
| 2020-12-31 | $17.84M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
ARS Pharmaceuticals generated $89.15M in revenue during NA 2024, up 297063.33% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
ARS Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $15.72M | 97.13% |
| 2025-03-31 | $7.97M | -90.79% |
| 2024-12-31 | $86.58M | 4086.70% |
| 2024-09-30 | $2.07M | 313.60% |
| 2024-06-30 | $500.00K | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | -100.00% |
| 2023-06-30 | $10.00K | -50.00% |
| 2023-03-31 | $20.00K | -101.52% |
| 2022-12-31 | $-1.32M | -796.30% |
| 2022-09-30 | $189.00K | -59.27% |
| 2022-06-30 | $464.00K | -30.02% |
| 2022-03-31 | $663.00K | -12.07% |
| 2021-12-31 | $754.00K | 42.80% |
| 2021-09-30 | $528.00K | -75.00% |
| 2021-06-30 | $2.11M | - |
| 2021-03-31 | $2.11M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | - |
ARS Pharmaceuticals generated $15.72M in revenue during Q2 2025, up 97.13% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
ARS Pharmaceuticals Revenue Breakdown
ARS Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 |
|---|---|
| Product | $7.25M |
Latest
ARS Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Dec 24 | Sep 24 |
|---|---|---|---|
| Product | $12.80M | $6.69M | $568.00K |
Latest
ARS Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product (100.00%).
ARS Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INVA | Innoviva | $358.71M | $88.63M |
| NKTR | Nektar Therapeutics | $98.43M | $10.46M |
| SPRY | ARS Pharmaceuticals | $89.15M | $15.72M |
| TNGX | Tango Therapeutics | $42.07M | $3.18M |
| RLAY | Relay Therapeutics | $10.01M | $7.68M |
| PGEN | Precigen | $3.92M | $856.00K |
| UPB | Upstream Bio | $2.37M | $566.00K |
| SEPN | Septerna | $1.07M | $219.00K |
| OCS | Oculis | $883.00K | - |
| LENZ | LENZ Therapeutics | - | - |
| MNMD | Mind Medicine (MindMed) | - | - |